Antibacterial agent 138, a benzothiazole inhibitor, targets bacterial DNA gyrase and topoisomerase IV, exhibiting both favorable solubility and plasma protein binding. It demonstrates antibacterial activity against Gram-positive and Gram-negative strains and functions as a dual GyrB and ParE inhibitor [1].
